This session will cover the release of the new medication centanafadine (Simtriyo) for the treatment of ADHD, as its novel mechanism of action as a triple reuptake inhibitor is labeled as a CNS stimulant rather than something like the norepinephrine reuptake inhibitors that exist as non-stimulants. The session will cover how centanafadine works, its unique labeling, safety profile, and how to identify selling points from manufacturers versus actual clinical efficacy.
Link to attend is: go.ohiopharmacists.org/Sep26LunchLearn